PTC Therapeutics, Inc. Concurrent $100 Million Common Stock Offering and $287.5 Million Convertible Senior Notes Offering
Davis Polk advised the underwriter in connection with the SEC-registered offering by PTC Therapeutics, Inc. of 2,475,248 shares of its common stock and the initial purchaser in a concurrent…